Glanvac 6 Vaccine [Clostridium Chauvoei-Novyi Type B-Perfringens Type D-Septicum-Tetani-Corynebacterium Pseudotuberculosis (Ovis) Bacterin-Toxoid] is now approved in Canada for use in sheep.
Glanvac 6 is used as an aid in the prevention of caseous lymphadenitis (CLA or cheesy gland), enterotoxaemia (pulpy kidney disease), tetanus, black disease, malignant oedema (blackleg like disease) and blackleg in sheep and lambs and swelled head in rams.
Caseous lymphadenitis is a chronic disease of sheep. It is characterized by abscesses, containing a cheese-like green pus, in the superficial and internal lymph nodes (glands) and lungs. The disease is caused by Corynebacterium pseudotuberculosis (ovis) which gains entry through breaks or abrasions of the skin or mucous membranes. The disease is spread when superficial abscesses burst during handling or shearing with consequent contamination of the shearing floor, holding yards, dips and shearing tools. In a moist environment, the bacteria are able to survive for up to 8 months. It has been implicated as a cause of ill-thrift in ewes. Prevalence increases with age. Clean properties may become infected by the introduction of an infected animal.
Black disease occurs as a sequel to liver fluke infestation and can result in death. The use of Glanvac 6 as an aid in prevention of black disease does not protect against disease associated with liver fluke infection.
From the label
For use in healthy sheep.
It is important that the vaccine is kept properly mixed before and during use.
Primary vaccination: Shake well and administer 1 mL subcutaneously high on the neck, behind the ear, followed by a second 1-mL dose 4 to 6 weeks later.
Revaccination: Annual revaccination with a single 1-mL dose is recommended. Booster doses typically confer lifelong immunity against tetanus, blackleg and malignant oedema. Lifelong immunity is not established against enterotoxaemia (pulpy kidney), black disease or caseous lymphadenitis.
Immunity to Clostridial diseases is established approximately 10 days following initial vaccination. The second dose, given four to six weeks after the first, should ensure a high level of immunity against these diseases. Immunity against caseous lymphadenitis develops within two weeks of administration of the second dose. To achieve maximum protection against caseous lymphadenitis, lambs should be vaccinated 2 weeks before probable exposure to infection. Annual revaccination should therefore be timed to provide protection at times of maximum exposure to the infectious agent e.g. for caseous lymphadenitis, before shearing and dipping; for enterotoxaemia prior to transfer to lush pasture or grain feeding.
See product label for general vaccination recommendations and a full list of product precautions.